JunZhangMDPhD

Oncology • Kansas City, KS

Thoracic Cancer

Associate Professor

Join to view full profile

Dr. Zhang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhang's full profile

Already have an account?

Office
3901 Rainbow Blvd
Division Of Medical Oncology, Department Of Internal Medicine
Kansas City, KS 66160
Phone+1 913-588-2825

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2012
One Brooklyn Health System - Kingsbrook Jewish Medical CenterResidency, Internal Medicine, 2009 - 2012
University of California San Francisco School of MedicinePost-Doctoral Fellowship, 2006 - 2009
Dana-Farber Cancer Institute, Harvard Medical SchoolPost-Doctoral Fellowship, 2006 - 2006
Lousiana State University Health Science CenterPhD, Cancer Biology, Cellular Biology & Anatomy, 2000 - 2004
Hunan Medical UniversityClass of 1995

Certifications & Licensure

KS State Medical License 2019 - 2025
MO State Medical License 2021 - 2025
IA State Medical License 2015 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients Start of enrollment: 2021 Apr 12
Recruiting
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Start of enrollment: 2021 Sep 14
Recruiting
Phase 2
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC Start of enrollment: 2022 Jul 21
Recruiting
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) Start of enrollment: 2020 Jul 29
Recruiting
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. Start of enrollment: 2019 Nov 05
Terminated
Phase 2
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Start of enrollment: 2018 Dec 26
Recruiting
Phase 1, Phase 2
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Start of enrollment: 2021 Apr 01
Active, not recruiting
Phase 3
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Start of enrollment: 2020 Sep 11
Active, not recruiting
Phase 3
Roles: Contact
PRO1184 for Advanced Solid Tumors Start of enrollment: 2022 Dec 07
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
Christine M Bestvina, Jared H L Hara, Theodore Karrison, Benjamen Bowar, Janet Chin
Clinical Lung Cancer. 2024-12-01
5 citations
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.
Caicun Zhou, Chongyang Li, Libo Luo, Xin Li, Keyi Jia
Cancer Cell. 2024-07-08
Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis.
Mohamed Rahouma, Nathan Mynard, Massimo Baudo, Sherif Khairallah, Shaikha Al-Thani
Cancers. 2024-03-13

Professional Memberships

American Society of Clinical Oncology - ASCO
Member